Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-03-05 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Regulatory Filings Classification · 85% confidence The document is a standardized monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing movements in share capital, issued shares, treasury shares, share option schemes, and share repurchases. It is not an earnings release, proxy statement, AGM material, or quarterly/annual report, and primarily serves as a regulatory filing. There is no indication it is merely announcing the publication of a report, but rather it constitutes a required regulatory submission. Therefore it best fits under the fallback category “Regulatory Filings” (RNS).
2025-03-05 English
PROFIT ALERT
Earnings Release Classification · 82% confidence The document is a Hong Kong Stock Exchange announcement made under listing rule requirements, providing key preliminary financial results (revenue and profit guidance) for the full year ended December 31, 2024. It is not a full annual report, nor is it merely an announcement of publication. It provides headline earnings information (key highlights only) and thus falls under an Earnings Release. FY 2024
2025-02-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 89% confidence The document is Form FF301 – a monthly return under Chapter 19B of the HKEX Listing Rules detailing movements in share capital, issued shares, treasury shares, and related transactions. It is a routine regulatory submission to the exchange rather than an annual report, earnings release, dividend notice, or a standalone management/financial report. Hence, it falls into the general “Regulatory Filings” fallback category.
2025-02-05 English
CONTINUING CONNECTED TRANSACTIONS (1) THE 2024 ANNUAL CAP BEING EXCEEDED AND (2) REVISION OF THE 2025 AND 2026 ANNUAL CAPS
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Stock Exchange announcement disclosing a breach of the 2024 annual cap under an existing Exclusive Promotion Services Cooperation Agreement (a continuing connected transaction under Listing Rules Chapter 14A) and the board’s revision of the 2025 and 2026 caps. It does not present financial results (ER/IR), detailed report content (10-K/IR), nor fall into any specialized category (e.g. M&A, dividend, proxy, ESG). It is a regulatory compliance announcement under the Listing Rules, making it a general “Regulatory Filings” item.
2025-01-24 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (FF305) filed by Simcere Pharmaceutical Group under the Hong Kong Listing Rules, detailing multiple repurchases of its own shares and their cancellation. This is a regulatory filing about the company’s share buyback activity, fitting the “Transaction in Own Shares” category.
2025-01-23 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules (Main Board Rule 13.25A/GEM Rule 17.27A) detailing changes in issued shares and extensive repurchases of treasury shares. It lists the dates, quantities and prices of shares repurchased for cancellation. This is clearly a report of the company’s own share repurchase transactions under listing rules, which corresponds to the "Transaction in Own Shares" category.
2025-01-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.